Rockefeller Capital Management’s First Tracks Biotherapeutics TRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding TRAX
Rockefeller Capital Management's TRAX Position: Q3 2026 in Review
Rockefeller Capital Management reduced its First Tracks Biotherapeutics (TRAX) stake by 1.3% in Q3 2026, selling an estimated $57.1K and leaving 115,476 shares worth $4.09M. The position accounts for 0.01% of the portfolio, ranked #1087.
Rockefeller Capital Management first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.
- Rockefeller Capital Management held 115,476 shares of First Tracks Biotherapeutics worth $4.09M as of Q3 2026.
- Rockefeller Capital Management sold 1,463 First Tracks Biotherapeutics shares in Q3 2026, an estimated $57.1K.
- First Tracks Biotherapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #1087 holding.
- Rockefeller Capital Management first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
- 182 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.